The FDA database lists a supplement dated 14 October to Fresenius Kabi USA's abbreviated new drug application for daptomycin, a generic of the intravenous lipopeptide antibiotic. The record gives no detail of what the supplement changed. Supplements to generic applications usually concern manufacturing, labelling alignment or packaging.
This is an administrative action. It does not signal a new indication, a safety finding or a change in how daptomycin should be used. Its direct relevance outside the US is limited.
- No change to daptomycin indications or dosing follows from this record.
- Generic daptomycin supplements usually concern manufacturing or labelling, not safety.
- Daptomycin remains an option for MRSA bacteraemia and complicated skin infection.
- Check local formularies for which daptomycin product is supplied.
Why it matters
Regulatory listings do not all carry clinical news, and this one does not.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free